228 related articles for article (PubMed ID: 14567019)
21. Pseudomyxoma Peritonei.
Bartoška P; Antoš F; Vítek P; Marx J; Kopic J; Holečková P
Klin Onkol; 2019; 32(5):329-332. PubMed ID: 31610663
[TBL] [Abstract][Full Text] [Related]
22. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin.
Järvinen P; Ristimäki A; Kantonen J; Lepistö A
Scand J Surg; 2013; 102(3):145-51. PubMed ID: 23963027
[TBL] [Abstract][Full Text] [Related]
24. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
25. One of the most difficult management problems in surgery is pseudomyxoma peritonei. Foreword.
Wells SA
Curr Probl Surg; 2008 Aug; 45(8):521. PubMed ID: 18590841
[No Abstract] [Full Text] [Related]
26. Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate.
Chua TC; Liauw W; Zhao J; Morris DL
Ann Surg; 2011 Apr; 253(4):769-73. PubMed ID: 21475018
[TBL] [Abstract][Full Text] [Related]
27. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
28. Ten years experience in the treatment of pseudomyxoma peritonei by cytoreduction, peritonectomy and semi-closed hyperthermic antiblastic peritoneal perfusion.
De Simone M; Vaira M; Caponi A; Ciaccio B; Fiorentini G; Turrisi G; Ferri L; Buti G
In Vivo; 2006; 20(6A):725-7. PubMed ID: 17203755
[TBL] [Abstract][Full Text] [Related]
29. Management of pseudomyxoma peritonei.
Fallis SA; Moran BJ
J BUON; 2015 May; 20 Suppl 1():S47-55. PubMed ID: 26051332
[TBL] [Abstract][Full Text] [Related]
30. Pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndrome.
Pestieau SR; Esquivel J; Sugarbaker PH
Ann Surg Oncol; 2000 Apr; 7(3):199-203. PubMed ID: 10791850
[TBL] [Abstract][Full Text] [Related]
31. Management of an inguinal hernia in patients with pseudomyxoma peritonei.
Sugarbaker PH
Eur J Surg Oncol; 2017 Jun; 43(6):1083-1087. PubMed ID: 28131668
[TBL] [Abstract][Full Text] [Related]
32. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures.
Smeenk RM; Verwaal VJ; Zoetmulder FA
Eur J Surg Oncol; 2006 Mar; 32(2):186-90. PubMed ID: 16303281
[TBL] [Abstract][Full Text] [Related]
33. Low-dose Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) as an Alternative Therapy for Pleuropulmonary Involvement in Pseudomyxoma Peritonei.
Robella M; Vaira M; Borsano A; Mossetti C; DE Simone M
Anticancer Res; 2018 Feb; 38(2):929-932. PubMed ID: 29374723
[TBL] [Abstract][Full Text] [Related]
34. Mucin as a therapeutic target in pseudomyxoma peritonei.
Choudry HA; O'Malley ME; Guo ZS; Zeh HJ; Bartlett DL
J Surg Oncol; 2012 Dec; 106(7):911-7. PubMed ID: 22585683
[TBL] [Abstract][Full Text] [Related]
35. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
[TBL] [Abstract][Full Text] [Related]
36. Intraperitoneal hyperthermia in the management of pseudomyxoma peritonei.
Hsu KH; Chou CY; Chang YC
Hepatogastroenterology; 2007; 54(73):47-52. PubMed ID: 17419229
[TBL] [Abstract][Full Text] [Related]
37. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process.
Carr NJ; Cecil TD; Mohamed F; Sobin LH; Sugarbaker PH; González-Moreno S; Taflampas P; Chapman S; Moran BJ;
Am J Surg Pathol; 2016 Jan; 40(1):14-26. PubMed ID: 26492181
[TBL] [Abstract][Full Text] [Related]
38. Chemo-hyperthermic peritoneal perfusion (CHPP) for appendiceal pseudomyxoma peritonei.
Katayama K; Yamaguchi A; Murakami M; Koneri K; Nagano H; Honda K; Hirono Y; Goi T; Iida A; Ito H
Int J Clin Oncol; 2009 Apr; 14(2):120-4. PubMed ID: 19390942
[TBL] [Abstract][Full Text] [Related]
39. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei.
Ronnett BM; Seidman JD
Am J Surg Pathol; 2003 May; 27(5):650-7. PubMed ID: 12717249
[TBL] [Abstract][Full Text] [Related]
40. Adenocarcinoma of the appendix with extra-appendicular spread: Clinico-surgical and histologic analysis of 27 cases.
Morera Ocón FJ; Camps Vilata B; Muñoz Forner E; Navarro Campoy C; Gallego Plazas J; Navarro Fos S
Med Clin (Barc); 2017 Aug; 149(4):153-156. PubMed ID: 28549831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
